Allarity Therapeutics (NASDAQ:ALLR) Announces Quarterly Earnings Results

Allarity Therapeutics (NASDAQ:ALLR) announced its earnings results on Friday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.05, Zacks reports.

Allarity Therapeutics Trading Down 10.6%

Shares of ALLR stock traded down $0.16 during trading hours on Friday, hitting $1.35. 258,413 shares of the company’s stock were exchanged, compared to its average volume of 174,502. The company has a market capitalization of $20.87 million, a PE ratio of -1.69 and a beta of 0.38. Allarity Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.35. The business’s 50 day simple moving average is $1.26 and its 200-day simple moving average is $1.16.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Jane Street Group LLC purchased a new position in shares of Allarity Therapeutics during the second quarter worth approximately $27,000. XTX Topco Ltd purchased a new position in shares of Allarity Therapeutics in the fourth quarter worth $36,000. Geode Capital Management LLC increased its stake in shares of Allarity Therapeutics by 49.3% in the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after buying an additional 16,729 shares during the period. DRW Securities LLC purchased a new position in shares of Allarity Therapeutics in the fourth quarter worth $133,000. Finally, Citadel Advisors LLC purchased a new position in shares of Allarity Therapeutics in the third quarter worth $149,000. 11.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ALLR shares. Ascendiant Capital Markets lifted their target price on shares of Allarity Therapeutics from $9.50 to $9.75 and gave the company a “buy” rating in a research report on Friday, April 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $9.75.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.